DanCann Pharma A/S submits new Application to the Danish Medicine Agency for authorisation to produce cannabis intermediate products
COPENHAGEN, December 17, 2020 – DanCann Pharma A/S (“DanCann Pharma”) (SS: DANCAN), a Danish pharmaceutical biotechnology company powered by cannabinoids, today announced that it has submitted a new Application to the Danish Medicine Agency (DMA) for approval for authorisation to produce cannabis intermediate products.On 1 January 2018, the four-year medicinal cannabis pilot programme was introduced. As a result, the Danish Medicines Agency is granting authorisations to produce cannabis intermediate products in accordance with section 9(1) of the Act on a Medicinal Cannabis Pilot Programme.